Theriva Biologics Inc. (TOVX) shares are trading significantly higher on Friday, fueled by a wave of positive news and events. This week has been particularly eventful for the company, starting with the announcement that the U.S. Food and Drug Administration (FDA) granted its VCN-01 treatment for retinoblastoma, the most common type of eye cancer in children, the prestigious Rare Pediatric Drug Designation (RPDD). This designation signifies the FDA’s recognition of VCN-01’s potential to address a serious and life-threatening condition in children.
Adding to the positive sentiment, Theriva Biologics received a notice of allowance for a U.S. Patent application focused on “Beta-Lactamase Formulations & Uses Thereof” for treating c. difficile disease. This patent approval strengthens the company’s intellectual property portfolio and underscores its commitment to developing innovative therapies for challenging medical conditions.
Further contributing to the stock’s momentum is the recent reverse stock split that took effect on Monday. This split reduced the stock’s float to less than one million shares, which has likely contributed to the observed price volatility.
For those interested in participating in the market for Theriva Biologics, either by purchasing shares or exploring alternative investment strategies, there are several avenues to consider. Purchasing shares is typically done through a brokerage account. Many brokerage platforms offer fractional shares, allowing investors to own portions of stock without buying an entire share, making investing in high-priced stocks more accessible.
For those seeking to bet against the company, a more complex process is involved. Access to an options trading platform or a broker who allows short selling is necessary. Shorting involves borrowing shares to sell, aiming to profit from a price decline. Alternatively, buying put options or selling call options at a strike price above the current share price can also offer potential profit opportunities from a price decrease.
According to Benzinga Pro, Theriva Biologics shares are up 9.57% at $5.15 at the time of publication on Friday. The company’s recent successes, combined with the reduced float from the reverse stock split, have created a dynamic environment for TOVX stock, making it a potential point of interest for investors seeking exposure to the biotechnology sector.
